During the last session, Candel Therapeutics Inc (NASDAQ:CADL)’s traded shares were 0.53 million, with the beta value of the company hitting -0.74. At the end of the trading day, the stock’s price was $4.57, reflecting an intraday gain of 0.88% or $0.04. The 52-week high for the CADL share is $14.60, that puts it down -219.47 from that peak though still a striking 17.07% gain since the share price plummeted to a 52-week low of $3.79. The company’s market capitalization is $215.87M, and the average intraday trading volume over the past 10 days was 0.85 million shares, and the average trade volume was 1.13 million shares over the past three months.
Candel Therapeutics Inc (CADL) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. CADL has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.24.
Candel Therapeutics Inc (NASDAQ:CADL) trade information
Candel Therapeutics Inc (CADL) registered a 0.88% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 0.88% in intraday trading to $4.57, hitting a weekly high. The stock’s 5-day price performance is -4.19%, and it has moved by -48.65% in 30 days. Based on these gigs, the overall price performance for the year is -22.41%. The short interest in Candel Therapeutics Inc (NASDAQ:CADL) is 4.47 million shares and it means that shorts have 4.27 day(s) to cover.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -43.86%. While earnings are projected to return 13.60% in 2025, the next five years will return 16.34% per annum.
CADL Dividends
Candel Therapeutics Inc is due to release its next quarterly earnings on 2025-Mar-12. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Candel Therapeutics Inc (NASDAQ:CADL)’s Major holders
Candel Therapeutics Inc insiders own 18.54% of total outstanding shares while institutional holders control 44.15%, with the float percentage being 54.20%. NORTHPOND VENTURES, LLC is the largest shareholder of the company, while 96.0 institutions own stock in it. As of 2024-06-30, the company held over 1.94 million shares (or 6.477% of all shares), a total value of $12.0 million in shares.
The next largest institutional holding, with 0.82 million shares, is of VANGUARD GROUP INC’s that is approximately 2.8035% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $5.08 million.
Also, the Mutual Funds coming in first place with the largest holdings of Candel Therapeutics Inc (CADL) shares are Fidelity Select Portfolios-Biotechnology Portfolio and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund. Data provided on Feb 28, 2025 indicates that Fidelity Select Portfolios-Biotechnology Portfolio owns about 5.54 shares. This amounts to just over 11.74 percent of the company’s overall shares, with a $25.34 million market value. The same data shows that the other fund manager holds slightly less at 866.65, or about 1.83% of the stock, which is worth about $3.96 million.
